The EU approves Dupixent as the first targeted therapy for uncontrolled COPD patients.

EU approves Dupixent as first-ever targeted therapy for COPD patients. Regeneron Pharmaceuticals' Dupixent received EU approval for adults with uncontrolled COPD and raised blood eosinophils. Two phase 3 studies show Dupixent reduces exacerbations, improves lung function, and enhances health-related quality of life. Dupixent is the first new COPD treatment in over a decade and a novel option for about 220,000 EU adults.